Week in Review: Fosun and TPG Offer $369 Million for Chindex

Fosun Pharma and TPG, a US private equity company, teamed up to offer $369 million to take China hospital operator Chindex private; Harbin Gloria Pharma acquired Shanghai Huatuo Medical Science, a maker of TCM products, for $170 million; Tonghua Shuanglong Chemical paid $178 million to acquire Jinbao Pharma in a cash and stock deal; Citic Private Equity is reportedly seeking funds to buy Biosensors, a China cardiovascular device company that is worth $1.2 billion; Lee’s Pharma in-licensed China rights to tafoxiparin, a clinical-stage labor-inducing drug from Dilafor of Sweden; Solentim, a UK medical device maker, will market its CellMetric device in China through two China distribution companies; and Dr. Jonathan Wang discussed OrbiMed’s China investment strategies in an exclusive interview with ChinaBio® Today. More details…. Stock Symbols: (SHA: 600196; HK: 2196) (NSDQ: CHDX) (SHE: 002437) (SHE: 300108) (HK: 950) Share this with colleagues: // //